Cytokine Release Syndrome Pipeline Insights 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND

DelveInsight's "Cytokine Release Syndrome Pipeline Insight" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cytokine Release Syndrome pipeline landscape. It covers the Cytokine Release Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cytokine Release Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Cytokine Release Syndrome pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Cytokine Release Syndrome Pipeline Report to explore emerging therapies, key Cytokine Release Syndrome Companies, and future Cytokine Release Syndrome treatment landscapes @ Cytokine Release Syndrome Pipeline Outlook Report- https://www.delveinsight.com/sample-request/cytokine-release-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Cytokine Release Syndrome Pipeline Report
• In February 2025:- Hoffmann-La Roche:- The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.
• In January 2025:- CytoAgents Inc.:- The first phase of the study will be an open-label, dose escalation, safety assessment in a group of patients, and will also collect data to investigate the potential benefit of CTO1681, initiated prior to CAR T-cell therapy, in preventing or reducing certain toxicities or side effects associated with CAR T-cell therapy, such as cytokine release syndrome (CRS).
• DelveInsight's Cytokine Release Syndrome pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Cytokine Release Syndrome treatment.
• The leading Cytokine Release Syndrome Companies such as Biocon Limited, Olatec Therapeutics LLC, Novartis Pharmaceuticals and others.
• Promising Cytokine Release Syndrome Therapies such as CTO1681 10 μg, Itacitinib, Itolizumab IV infusion, Ruxolitinib, and others.

Discover how the Cytokine Release Syndrome treatment paradigm is evolving. Access DelveInsight's in-depth Cytokine Release Syndrome Pipeline Analysis for a closer look at promising breakthroughs @ Cytokine Release Syndrome Clinical Trials and Studies- https://www.delveinsight.com/sample-request/cytokine-release-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cytokine Release Syndrome Emerging Drugs Profile
• Canakinumab: Novartis
Canakinumab is an interleukin (IL)-1β blocker indicated to treat certain periodic fever syndromes, such as cryopyrin-associated periodic syndromes and systemic juvenile idiopathic arthritis. Novartis is conducting phase III trial, called CAN-COVID which will evaluate the drug's efficacy in treating a type of severe immune overreaction called cytokine release syndrome (CRS) related to Covid-19 pneumonia.

• Itacitinib: Incyte Corporation
Itacitinib is a potent, selective JAK1 inhibitor which is being clinically evaluated in several inflammatory diseases. It is currently being evaluated in phase II stage for the prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy.

• Dapansutrile: Olatec Therapeutics LLC
Dapansutrile is being developed by Olatec Therapeutics LLC for the treatment of Cytokine Release Syndrome. It is currently being evaluated in phase II trial to determine safety and efficacy of Dapansutrile for treatment of moderate COVID-19 symptoms and evidence of Early Cytokine Release Syndrome.

The Cytokine Release Syndrome pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Cytokine Release Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cytokine Release Syndrome Treatment.
• Cytokine Release Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cytokine Release Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cytokine Release Syndrome market.

Get a detailed analysis of the latest innovations in the Cytokine Release Syndrome pipeline. Explore DelveInsight's expert-driven report today! @ Cytokine Release Syndrome Unmet Needs- https://www.delveinsight.com/sample-request/cytokine-release-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cytokine Release Syndrome Companies
Biocon Limited, Olatec Therapeutics LLC, Novartis Pharmaceuticals and others.

Cytokine Release Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Molecule Type

Cytokine Release Syndrome Products have been categorized under various Molecule types such as
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Download DelveInsight's latest report to gain strategic insights into upcoming Cytokine Release Syndrome Therapies and key Cytokine Release Syndrome Developments @ Cytokine Release Syndrome Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/cytokine-release-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Cytokine Release Syndrome Pipeline Report
• Coverage- Global
• Cytokine Release Syndrome Companies- Biocon Limited, Olatec Therapeutics LLC, Novartis Pharmaceuticals and others.
• Cytokine Release Syndrome Therapies- CTO1681 10 μg, Itacitinib, Itolizumab IV infusion, Ruxolitinib, and others.
• Cytokine Release Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cytokine Release Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Cytokine Release Syndrome drug development? Find out in DelveInsight's exclusive Cytokine Release Syndrome Pipeline Report-access it now! @ Cytokine Release Syndrome Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/cytokine-release-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Cytokine Release Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cytokine Release Syndrome - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Cytokine Release Syndrome Collaboration Deals
9. Late Stage Products (Phase III)
10. Canakinumab: Novartis
11. Mid Stage Products (Phase II)
12. Itacitinib: Incyte Corporation
13. Dapansutrile: Olatec Therapeutics LLC
14. Drug profiles in the detailed report.....
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report.....
18. Pre-clinical and Discovery Stage Products
19. Drug Name: Company Name
20. Inactive Products
21. Cytokine Release Syndrome Key Companies
22. Cytokine Release Syndrome Key Products
23. Cytokine Release Syndrome- Unmet Needs
24. Cytokine Release Syndrome- Market Drivers and Barriers
25. Cytokine Release Syndrome- Future Perspectives and Conclusion
26. Cytokine Release Syndrome Analyst Views
27. Cytokine Release Syndrome Key Companies
28. Appendix

List of Top Selling Market Research Reports in 2025

Radiation retinopathy market- https://www.delveinsight.com/sample-request/radiation-retinopathy-market
Immune checkpoints activators market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Cystic fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Palmoplantar pustulosis market- https://www.delveinsight.com/report-store/palmoplantar-pustulosis-market
Smoking cessation market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Tay-Sachs market- https://www.delveinsight.com/report-store/tay-sachs-disease-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market
Open angle glaucoma market- https://www.delveinsight.com/report-store/glaucoma-market
Acute myeloid leukemia market- https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market
Asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Bone growth stimulators market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Cardiogenic shock market- https://www.delveinsight.com/report-store/cardiogenic-shock-market
Pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
Pediatric brain tumor market- https://www.delveinsight.com/report-store/pediatric-brain-tumors-market
Pelizaeus-merzbacher disease market- https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
Peritoneal carcinomatosis market- https://www.delveinsight.com/report-store/peritoneal-carcinomatosis-pc-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.